News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Takes Over Marketing of Maalox for Oral Suspension from Aventis Pharma to Start Exclusive Marketing

November 20,2003

Tokyo, Japan - November 20, 2003 -Yamanouchi Pharmaceutical Co., Ltd. (president: Toichi Takenaka) announced that it reached an agreement with Aventis Pharma Ltd. (chairman & president (CEO): James Mitchum) according to which Aventis will transfer the marketing of the peptic ulcer and gastritis treatment Maalox for Oral Suspension to Yamanouchi. This product has been comarketed by the two companies under the same brand name. Yamanouchi will start exclusive marketing on January 1, 2004.

Indicated for gastroduodenal ulcers and gastritis, Maalox for Oral Suspension has been comarketed by Yamanouchi and Aventis Pharma since its launching in 1994. Following this deal, Yamanouchi will be solely responsible for the sale of the product to wholesalers and the supply of information to and its collection from medical professionals. Aventis will continue to be responsible for manufacturing.

For Yamanouchi, the drug for peptic ulcer and gastritis Gaster (famotidine) is a mainstay product, and it regards gastroenterology as one of the focus areas. With the exclusive marketing of Maalox for Oral Suspension, Yamanouchi intends to strengthen its presence in this franchise field.

Product Profile

Brand name:
Maalox for Oral Suspension

Generic name:
dried aluminum hydroxide + magnesium hydroxide

control of acid and improvement of symptoms associated with gastroduodenal ulcers, gastritis, and upper gastrointestinal dysfunction

Dosageand administration:
In general, administer 1.6-4.8 g per day in divided doses to adults. Suspend in water before administration at a ratio of about 10 mL per gram. Maalox for Oral Suspension can also be ingested as is without suspending it in water. The dosage should be adjusted according to the patients' age and symptoms.

360g (1.2g x 300 sachets)
1,260g (1.2g x 1,050sachets)
2,160g (1,2g x 1,800sachets) *
* This package will be added following the transfer of marketing from Aventis Pharma.

Yamanouchi Pharmaceutical Co., Ltd.

Aventis Pharma Ltd.